0001193125-19-162638.txt : 20190531 0001193125-19-162638.hdr.sgml : 20190531 20190531143732 ACCESSION NUMBER: 0001193125-19-162638 CONFORMED SUBMISSION TYPE: 15-12B PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20190531 DATE AS OF CHANGE: 20190531 EFFECTIVENESS DATE: 20190531 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Orexigen Therapeutics, Inc. CENTRAL INDEX KEY: 0001382911 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 651178822 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12B SEC ACT: 1934 Act SEC FILE NUMBER: 001-33415 FILM NUMBER: 19869948 BUSINESS ADDRESS: STREET 1: 3344 N. TORREY PINES CT. STREET 2: SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: (858) 875-8600 MAIL ADDRESS: STREET 1: 3344 N. TORREY PINES CT. STREET 2: SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 15-12B 1 d742028d1512b.htm 15-12B 15-12B

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-33415

 

 

Orexigen Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

3344 N. Torrey Pines Ct., Suite 200

La Jolla, CA 92037

(858) 875-8600

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, par value $0.001 per share

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)    

☒

Rule 12g-4(a)(2)    

☐

Rule 12h-3(b)(1)(i)    

☒

Rule 12h-3(b)(1)(ii)    

☐

Rule 15d-6    

☐

Rule 15d-22(b)    

☐

Approximate number of holders of record as of the certification or notice date: 0

Pursuant to the requirements of the Securities Exchange Act of 1934 Orexigen Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date:    May 31, 2019     

Orexigen Therapeutics, Inc.

       By:   

/s/ Thomas P. Lynch

      

Name:

  

Thomas P. Lynch

      

Title:

  

Chief Administrative Officer, General Counsel, President, Secretary and Treasurer